Inclusion Criteria:  irrespective of sex; aged between 45 and 79 years; with office-measured seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic; diagnosed of type 2 diabetes mellitus (T2DM), currently on diabetic therapy; a glycosylated hemoglobin (HbA1c) ≤ 8.5%; informed consent provided and long-term follow-up possible  Exclusion Criteria:  administration of any antihypertensive medications within 1 month; a history of hypoglycemic coma / seizure; confirmed diagnosis of type 1 diabetes mellitus; alanine-aminotransferase (ALT) or aspartate-aminotransferase (AST) over three times the upper limit of normal; estimated glomerular filtration rate < 45 ml/min/1.73m2; a history of congestive heart failure with left ventricular ejection fraction < 40%, requiring treatment with renin-angiotensin system (RAS) blockers; coronary artery disease requiring RAS blockers for secondary prevention; acute on-set of stroke within 6 months prior to randomization; a ratio of urinary albumin (in mg/L) to urinary creatinine (in g/L) (ACR) ≥ 300 mg/g; a history of primary or secondary renal diesease requiring a therapy using glucocorticoid or immunity inhibitor; a history of polycystic kidney; known contraindications for the active study medications; a history of psychological or mental disorder; pregnancy or currently planning to have babies or lactation; severe diseases such as severe valvular heart diseases; an expected residual life span less than 3 years; a malignancy that clinical investigators consider as unsuitable to participate; currently participating in another clinical trial.